LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Insmed Incorporated ("Insmed" or the "Company") (Nasdaq: INSM). Investors who purchased or otherwise acquired shares between March 18, 2013 and June 8, 2016 (the “Class Period”), are encouraged to contact the firm in advance of the September 13, 2016 lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, Insmed made false and/or misleading statements and/or failed to disclose that: the data on which Insmed’s European marketing authorization application relied for its lead product candidate for the treatment of NTM lung disease, Arikayce, was not likely to support approval by the European Medicines Agency (“EMA”); Arikayce’s approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely than the Company had led investors to believe; and as a result of the above, Insmed’s public statements were materially false and misleading at all relevant times.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.